Search results
Results from the WOW.Com Content Network
a cylindrical small glass bottle with a screw cap used as a culture medium holder Biosafety cabinet: used to work with dangerous organisms and to work sterile Blood collection bottle: to collect blood by venipuncture: Brittany: a process of sterilization from spore-bearing bacteria: Bunsen burner: used to work aseptic on the benc Candle jar
ZF2001, trade-named Zifivax or ZF-UZ-VAC-2001, is an adjuvanted protein subunit COVID-19 vaccine developed by Anhui Zhifei Longcom in collaboration with the Institute of Microbiology at the Chinese Academy of Sciences. [2] [3] The vaccine candidate is in Phase III trials with 29,000 participants in China, Ecuador, Malaysia, Pakistan, and ...
AD5-nCOV, trade-named Convidecia, is a single-dose [2] viral vector vaccine for COVID-19 that is also used as an inhaled booster. It was developed by CanSino Biologics , with Phase III trials conducted in Argentina , [ 3 ] Chile , [ 4 ] Mexico , [ 5 ] Pakistan , [ 6 ] Russia , [ 7 ] and Saudi Arabia [ 8 ] with 40,000 participants.
SCB-2019 is a protein subunit COVID-19 vaccine developed by Clover Biopharmaceuticals using an adjuvant from Dynavax technologies. [2] Positive results of Phase I trials for the vaccine were published in The Lancet [ 3 ] and the vaccine completed enrollment of 29,000 participants in Phase II/III trials in July 2021. [ 4 ]
The Moderna COVID‑19 vaccine, sold under the brand name Spikevax, is a COVID-19 vaccine developed by the American company Moderna, the United States National Institute of Allergy and Infectious Diseases (NIAID), and the Biomedical Advanced Research and Development Authority (BARDA).
All RMPs for COVID‑19 vaccines will be published on the EMA's website. [136] The EMA published guidance for developers of potential COVID‑19 vaccines on the clinical evidence to include in marketing authorization applications. [137] In November 2020, the CHMP started a rolling review of the Moderna vaccine for COVID‑19 known as mRNA-1273 ...
The initial uses would be for their candidate vaccines for Lassa fever, yellow fever, and rabies. [24] In July 2020, Tesla, Inc CEO Elon Musk announced via a Tweet that Tesla and CureVac had reached an agreement to produce portable "RNA microfactories" based on this technology to manufacture CureVac's COVID-19 vaccine candidate. [24]
Abdala, technical name CIGB-66, is a COVID-19 vaccine developed by the Center for Genetic Engineering and Biotechnology in Cuba. [2] This candidate, named after a patriotic drama by Cuban independence hero José Martí , is a protein subunit vaccine containing COVID-derived proteins that trigger an immune response. [ 3 ]